For instance, Cortellini et al. found that a decreased SMI was associated with reduced survival in advanced cancer patients who were treated with PD-1/PD-L1 checkpoint inhibitors, including those with melanoma, RCC, and lung cancer [33]. This evidence concerns the gene CD274 and renal cell carcinoma.